Onivyde for the therapy of multiple solid tumors

Haijun Zhang Department of Oncology, Zhongda Hospital, Medical School, Southeast University, Nanjing, People’s Republic of China Abstract: Drug delivery system based on nanobiotechnology can improve the pharmacokinetics and therapeutic index of chemotherapeutic agents, which has revoluti...

Full description

Bibliographic Details
Main Author:	Zhang H
Format:	Article
Language:	English
Published:	Dove Medical Press 2016-05-01
Series:	OncoTargets and Therapy
Subjects:	irinotecan PEP02 MM-398 Onivyde drug delivery system tumor therapy
Online Access:	https://www.dovepress.com/onivyde-for-the-therapy-of-multiple-solid-tumors-peer-reviewed-article-OTT

id	doaj-c47a32db7b5549ed98212527ee55b2ba
record_format	Article
spelling	doaj-c47a32db7b5549ed98212527ee55b2ba2020-11-24T21:28:02ZengDove Medical PressOncoTargets and Therapy1178-69302016-05-012016Issue 13001300727034Onivyde for the therapy of multiple solid tumorsZhang HHaijun Zhang Department of Oncology, Zhongda Hospital, Medical School, Southeast University, Nanjing, People’s Republic of China Abstract: Drug delivery system based on nanobiotechnology can improve the pharmacokinetics and therapeutic index of chemotherapeutic agents, which has revolutionized tumor therapy. Onivyde, also known as MM-398 or PEP02, is a nanoliposomal formulation of irinotecan which has demonstrated encouraging anticancer activity across a broad range of malignancies, including pancreatic cancer, esophago-gastric cancer, and colorectal cancer. This up-to-date review not only focuses on the structure, pharmacokinetics, and pharmacogenetics of Onivyde but also summarizes clinical trials and recommends Onivyde for patients with advanced solid tumors. Keywords: irinotecan, PEP02, MM-398, Onivyde, drug delivery system, tumor therapyhttps://www.dovepress.com/onivyde-for-the-therapy-of-multiple-solid-tumors-peer-reviewed-article-OTTirinotecanPEP02MM-398Onivydedrug delivery systemtumor therapy
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Zhang H
spellingShingle	Zhang H Onivyde for the therapy of multiple solid tumors OncoTargets and Therapy irinotecan PEP02 MM-398 Onivyde drug delivery system tumor therapy
author_facet	Zhang H
author_sort	Zhang H
title	Onivyde for the therapy of multiple solid tumors
title_short	Onivyde for the therapy of multiple solid tumors
title_full	Onivyde for the therapy of multiple solid tumors
title_fullStr	Onivyde for the therapy of multiple solid tumors
title_full_unstemmed	Onivyde for the therapy of multiple solid tumors
title_sort	onivyde for the therapy of multiple solid tumors
publisher	Dove Medical Press
series	OncoTargets and Therapy
issn	1178-6930
publishDate	2016-05-01
description	Haijun Zhang Department of Oncology, Zhongda Hospital, Medical School, Southeast University, Nanjing, People’s Republic of China Abstract: Drug delivery system based on nanobiotechnology can improve the pharmacokinetics and therapeutic index of chemotherapeutic agents, which has revolutionized tumor therapy. Onivyde, also known as MM-398 or PEP02, is a nanoliposomal formulation of irinotecan which has demonstrated encouraging anticancer activity across a broad range of malignancies, including pancreatic cancer, esophago-gastric cancer, and colorectal cancer. This up-to-date review not only focuses on the structure, pharmacokinetics, and pharmacogenetics of Onivyde but also summarizes clinical trials and recommends Onivyde for patients with advanced solid tumors. Keywords: irinotecan, PEP02, MM-398, Onivyde, drug delivery system, tumor therapy
topic	irinotecan PEP02 MM-398 Onivyde drug delivery system tumor therapy
url	https://www.dovepress.com/onivyde-for-the-therapy-of-multiple-solid-tumors-peer-reviewed-article-OTT
work_keys_str_mv	AT zhangh onivydeforthetherapyofmultiplesolidtumors
_version_	1725971934897766400

Onivyde for the therapy of multiple solid tumors

Similar Items